Bank of America (Merrill Lynch) upgraded Tesaro Inc (NASDAQ:TSRO) from Neutral to Buy in a report released today.
- Updated: October 10, 2016
Just yesterday Tesaro Inc (NASDAQ:TSRO) traded -0.63% lower at $117.91. Tesaro Inc’s 50-day moving average is $96.42 and its 200-day moving average is $68.96. The last stock price is up 43.94% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 1,364,793 shares of TSRO traded hands, up from an average trading volume of 1,009,710
Bank of America (Merrill Lynch) has upgraded Tesaro Inc (NASDAQ:TSRO) from Neutral to Buy in a report released on 10/10/2016.
Previously on 9/06/2016, Lake Street released a statement about Tesaro Inc (NASDAQ:TSRO) increased the target price from $0.00 to $114.00. At the time, this indicated a possible upside of 0.31%.
Recent Performance Chart
Tesaro Inc has 52 week low of $29.51 and a 52 week high of $110.48 and has a market capitalization of $0.
In addition to Bank of America (Merrill Lynch) reporting its stock price target, a total of 10 brokerages have issued a ratings update on the company. The average stock price target is $89.00 with 8 brokerages rating the stock a strong buy, 4 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.
Brief Synopsis On Tesaro Inc (NASDAQ:TSRO)
TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform. It offers VARUBI (rolapitant), which is an oral substance P/neurokinin 1 (NK-1) receptor antagonist for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. It is developing IV formulation of rolapitant, which has completed various Phase 1 clinical trials. Its niraparib is an orally active and poly (ADP-ribose) polymerase (PARP) inhibitor. Its immuno-oncology platform has immuno-oncology programs, which include TSR-022 and TSR-042.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.